资讯

technologynetworks1 个月
RNA Inhibitor Reduces “Bad Cholesterol” in Patients With Cardiovascular Disease
Lipoprotein(a) is believed to be a major carrier of oxidized phospholipids, considered a potent driver of inflammation and atherosclerosis. Olpasiran (manufactured by Amgen), a small interfering RNA, ...
Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with ...
is believed to be a major carrier of oxidized phospholipids, considered a potent driver of inflammation and atherosclerosis. Olpasiran (manufactured by Amgen), a small interfering RNA, blocks Lp(a ...